Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge D; PLATO Investigators. Andell P, et al. Among authors: cannon cp. J Am Heart Assoc. 2015 Oct 9;4(10):e002490. doi: 10.1161/JAHA.115.002490. J Am Heart Assoc. 2015. PMID: 26452988 Free PMC article. Clinical Trial.
Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Cannon CP, et al. Circulation. 1998 Feb 3;97(4):340-9. doi: 10.1161/01.cir.97.4.340. Circulation. 1998. PMID: 9468207 Clinical Trial.
The antiplatelet effects of ticlopidine and clopidogrel.
Sharis PJ, Cannon CP, Loscalzo J. Sharis PJ, et al. Among authors: cannon cp. Ann Intern Med. 1998 Sep 1;129(5):394-405. doi: 10.7326/0003-4819-129-5-199809010-00009. Ann Intern Med. 1998. PMID: 9735068 Review.
Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program.
Cannon CP, Hand MH, Bahr R, Boden WE, Christenson R, Gibler WB, Eagle K, Lambrew CT, Lee TH, MacLeod B, Ornato JP, Selker HP, Steele P, Zalenski RJ; National Heart Attack Alert Program (NHAAP) Coordinating Committee Critical Pathways Writing Group. Cannon CP, et al. Am Heart J. 2002 May;143(5):777-89. doi: 10.1067/mhj.2002.120260. Am Heart J. 2002. PMID: 12040337 Review.
Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry.
Bahit MC, Cannon CP, Antman EM, Murphy SA, Gibson CM, McCabe CH, Braunwald E; TIMI 9 Trial and TIMI 9 Registry. Thrombolysis In Myocardial Infarction. Bahit MC, et al. Among authors: cannon cp. Am Heart J. 2003 Jan;145(1):109-17. doi: 10.1067/mhj.2003.43. Am Heart J. 2003. PMID: 12514662
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E; OPUS-TIMI 16 Investigators. Cotter G, et al. Among authors: cannon cp. Am Heart J. 2003 Apr;145(4):622-7. doi: 10.1067/mhj.2003.6. Am Heart J. 2003. PMID: 12679757 Clinical Trial.
1,011 results